HUTCHMED (China) Limited
HMDCFOTCHealthcare● Active
$2.90
+$0.74(+34.26%)
Market Cap$2.5B
P/E Ratio—
52W High$3.815
52W Low$2.16
HUTCHMED (China) Limited (HMDCF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HMDCF · earnings · updated Jun 8, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 7, 2025EPS Actual
$0.26
Est. $0.29 · -10.5%
Revenue
$0.14B
Est. $0.33B · -58.0%
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 7, 2025
After Market Close
▼ Miss EPS▼ Miss Revenue
HMDCF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | $0.02 | — | — | — | $0.31B | — |
| ◌ Q1 FY2026 | Mar 17, 2026 | -$0.07 | — | — | — | $0.08B | — |
| ◌ Q1 FY2026 | Mar 5, 2026 | $0.50 | — | — | $0.27B | $0.29B | -6.7% |
| ▼ Q3 FY2025 | Aug 7, 2025 | $0.29 | $0.26 | -10.5% | $0.14B | $0.33B | -58.0% |
| ▲ Q1 FY2025 | Mar 19, 2025 | $0.01 | $0.01 | +75.0% | $0.32B | $0.32B | +1.6% |
| ◌ Q1 FY2025 | Feb 19, 2025 | — | — | — | — | — | — |
| ▲ Q3 FY2024 | Jul 31, 2024 | -$0.08 | $0.01 | +118.8% | $0.15B | $0.32B | -52.1% |
| — Q2 FY2024 | Jun 10, 2024 | — | $0.01 | — | $0.15B | — | — |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
$0.02
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 17, 2026
EPS Actual
—
EPS Est.
-$0.07
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 5, 2026
EPS Actual
—
EPS Est.
$0.50
EPS Surpr.
—
Revenue
$0.27B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
$0.26
EPS Est.
$0.29
EPS Surpr.
-10.5%
Revenue
$0.14B
Q1 FY2025
Mar 19, 2025Beat
EPS Actual
$0.01
EPS Est.
$0.01
EPS Surpr.
+75.0%
Revenue
$0.32B
Q1 FY2025
Feb 19, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Jul 31, 2024Beat
EPS Actual
$0.01
EPS Est.
-$0.08
EPS Surpr.
+118.8%
Revenue
$0.15B
Q2 FY2024
Jun 10, 2024
EPS Actual
$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.15B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2029 | $0.03 | $0.03 | $0.03 | 1 |
| Q1 FY2029 | $0.08 | $0.08 | $0.08 | 1 |
| Q4 FY2028 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q3 FY2028 | $0.02 | $0.02 | $0.02 | 1 |
| Q2 FY2028 | $0.50 | $0.50 | $0.50 | 1 |
| Q1 FY2028 | $0.29 | $0.29 | $0.29 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2029 | $0.5B | $0.5B | $0.5B | 1 |
| Q1 FY2029 | $0.5B | $0.5B | $0.5B | 1 |
| Q4 FY2028 | $0.3B | $0.3B | $0.3B | 1 |
| Q3 FY2028 | $0.3B | $0.3B | $0.3B | 1 |
| Q2 FY2028 | $0.3B | $0.3B | $0.3B | 1 |
| Q1 FY2028 | $0.3B | $0.3B | $0.3B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2025 | Aug 7, 2025 | -10.5% | $3.20 | $3.20 | +0.00% |
| ▲ Q1 FY2025 | Mar 19, 2025 | +75.0% | $3.20 | $3.20 | +0.00% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +118.8% | $3.82 | $3.82 | +0.00% |
| — Q2 FY2024 | Jun 10, 2024 | — | $3.82 | $3.82 | +0.00% |
| ▲ Q1 FY2024 | Mar 12, 2024 | +63.9% | $3.82 | $3.82 | +0.00% |
| — Q3 FY2023 | Sep 29, 2023 | — | $3.08 | $3.08 | +0.00% |
| ▲ Q3 FY2023 | Jul 31, 2023 | +193.5% | $3.00 | $2.71 | -9.67% |
| — Q1 FY2023 | Mar 31, 2023 | — | $2.65 | $2.65 | +0.00% |
Q3 FY2025+0.00%
Report Date
Aug 7, 2025
EPS Beat/Miss
-10.5%
Price Before
$3.20
Price After
$3.20
Q1 FY2025+0.00%
Report Date
Mar 19, 2025
EPS Beat/Miss
+75.0%
Price Before
$3.20
Price After
$3.20
Q3 FY2024+0.00%
Report Date
Jul 31, 2024
EPS Beat/Miss
+118.8%
Price Before
$3.82
Price After
$3.82
Q2 FY2024+0.00%
Report Date
Jun 10, 2024
EPS Beat/Miss
—
Price Before
$3.82
Price After
$3.82
Q1 FY2024+0.00%
Report Date
Mar 12, 2024
EPS Beat/Miss
+63.9%
Price Before
$3.82
Price After
$3.82
Q3 FY2023+0.00%
Report Date
Sep 29, 2023
EPS Beat/Miss
—
Price Before
$3.08
Price After
$3.08
Q3 FY2023-9.67%
Report Date
Jul 31, 2023
EPS Beat/Miss
+193.5%
Price Before
$3.00
Price After
$2.71
Q1 FY2023+0.00%
Report Date
Mar 31, 2023
EPS Beat/Miss
—
Price Before
$2.65
Price After
$2.65
Avg Beat Reaction-2.42%
Avg Miss Reaction+0.00%
Beat Rate4 / 8 quarters
Largest Move-9.67% (Q3 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HMDCF ends December
HUTCHMED (China) Limited (HMDCF) most recently reported earnings on August 7, 2025 for Q3 FY2025, posting EPS of $0.26 — missing the analyst consensus of $0.29 by -10.5%. The next HMDCF earnings date is expected around September 1, 2026.
Each quarter, investors track HMDCF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HMDCF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HMDCF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HMDCF earnings · 5 questionsHUTCHMED (China) Limited's next earnings report is expected around September 1, 2026. HMDCF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HMDCF historically reports after market close (AMC).
HMDCF earnings datewhen is HMDCF earningsHMDCF next earnings datewhen does HMDCF report earningsHMDCF earnings calendar
▸ Source: FMP · HUTCHMED (China) Limited SEC filings · US GAAP · HUTCHMED (China) Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026